Revlimid (lenalidomide) is a brand-name oral capsule that’s prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...
FDA approved Adcetris, Revlimid, and Rituxan for relapsed/refractory LBCL patients ineligible for auto-HSCT or CAR-T therapy, based on ECHELON-3 trial results. The combination therapy showed ...
Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...
FDA approved Amneal's generic lenalidomide capsules, referencing Celgene's Revlimid, for manufacturing and sale starting in 2026. Amneal launched mesalamine 800 mg delayed-release tablets for ...
LOS ANGELES, June 3 (Reuters) - Celgene Corp.'s blood cancer drug Revlimid combined with a low-dose of steroid resulted in a higher one-year survival rate than the drug plus the higher, standard dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results